Skip Navigation LinksOA_ADAP_MM_2023-18_Addition_of_Oral_Paliperidone_to_the_ADAP_Formulary

State of Cal Logo

State of California—Health and Human Services Agency
California Department of Public Health

ADAP MM 2023-18

ADAP Enrollment Workers

Addition of Oral Paliperidone to the ADAP Formulary

​ADAP Management Memo 2023-18: Addition of Oral Paliperidone to the ADAP Formulary

Effective October 13, 2023, oral extended release paliperidone (INVEGA®) has been added to the ADAP formulary.

People with HIV (Human Immunodeficiency Virus) are at an increased risk of mental health disorders including, in some cases, psychotic disorders. A psychotic mental health condition can significantly impair overall quality of life and interfere with access to HIV treatment. Psychotic disorders, such as schizophrenia or schizoaffective disorder, require effective medication management. Paliperidone is a proven effective antipsychotic medication that is currently available on the ADAP formulary as a long-acting injection. Adding extended-release oral paliperidone (INVEGA®) provides another option to improve antipsychotic treatment and help patients improve their health, quality of life, and HIV treatment.

ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP drug formulary has been updated to reflect the addition of oral paliperidone.

If you have any questions regarding the addition of these medications to the ADAP formulary, please contact the OA Formulary Specialist, James Vo (


Thank you, 

electronic signature of Joseph Lagrama

Joseph Lagrama
ADAP Branch Chief
California Department of Public Health
Page Last Updated :